Close Menu

NEW YORK (GenomeWeb) – Leerink on Monday initiated coverage of Myriad Genetics with a Market Perform rating and a $31 12-month price target on the company's stock.

In a research note, analyst Puneet Souda noted that while Myriad is still a dominant leader in hereditary cancer testing, it is still trying to stabilize that business in the wake of the 2013 US Supreme Court decision on gene patenting, while also diversifying its portfolio to drive future growth.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.